Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Ryoko TanakaYushi UekiShusuke OhshimaJo OmataYusuke YokoyamaTakeshi TakahashiRyusuke ShodoKeisuke YamazakiKohei OhtakiTakafumi TogashiArata HoriiPublished in: International journal of clinical oncology (2024)
NAC using the PCE regimen for patients with locally advanced HNSCC, including cisplatin-ineligible patients, has acceptable toxicity and favorable efficacy.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- phase ii study
- rectal cancer
- squamous cell carcinoma
- end stage renal disease
- radiation therapy
- sentinel lymph node
- newly diagnosed
- lymph node
- ejection fraction
- chronic kidney disease
- transcription factor
- prognostic factors
- peritoneal dialysis
- early stage
- clinical trial
- open label
- patient reported